The gold(I) mixed-ligand complexes involving O-substituted derivatives of 9-deazahypoxanthine (HLn) and triphenylphosphine (PPh3) with the general formula [Au(Ln)(PPh3)] (1-5) were prepared and thoroughly characterized by elemental analysis, FT-IR and multinuclear NMR spectroscopy, ESI+ mass spectrometry, single crystal X-ray (HL5 and complex 2) and TG/DTA analyses. Complexes 1-5 were evaluated for their in vitro antitumor activity against nine human cancer lines, i.e. MCF7 (breast carcinoma), HOS (osteosarcoma), A549 (adenocarcinoma), G361 (melanoma), HeLa (cervical cancer), A2780 (ovarian carcinoma), A2780R (ovarian carcinoma resistant to cisplatin), 22Rv1 (prostate cancer) and THP-1 (monocytic leukaemia), for their in vitro anti-inflammatory activity using a model of LPS-activated macrophages, and for their in vivo antiedematous activity by λ-carrageenan-induced hind paw edema model on rats. The results showed that the complexes 1-5 exhibit selective in vitro cytotoxicity against MCF7, HOS, 22Rv1, A2780 and A2780R, with submicromolar IC50 values for 2 against the MCF7 (0.6 µM) and HOS (0.9 µM). The results of in vitro cytotoxicity screening on primary culture of human hepatocytes (HEP220) revealed up to 30-times lower toxicity of compounds against healthy cells as compared with cancer cells. Additionally, the complexes 1-5 significantly influence the secretion and expression of pro-inflammatory cytokines TNF-α and IL-1β by a similar manner as a commercially used anti-arthritic drug Auranofin. The tested complexes also significantly influence the rate and overall volume of the edema, caused by the intraplantar application of λ-carrageenan polysaccharide to rats. Based on these promising results, the presented compounds could qualify to become feasible candidates for advanced testing as potential antitumor and anti-inflammatory drug-like compounds.

Department of Human Pharmacology and Toxicology Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Brno Czech Republic

Regional Centre of Advanced Technologies and Materials and Department of Cell Biology and Genetics Faculty of Science Palacký University Olomouc Czech Republic

Regional Centre of Advanced Technologies and Materials and Department of Inorganic Chemistry Faculty of Science Palacký University Olomouc Czech Republic

See more in PubMed

Gielen M, Tiekink ERT (2005) Metallotherapeutic Drugs and Metal-based Diagnostic Agents: The Use of Metals in Medicine. London: John Wiley and Sons, Ltd., Chichester, England.

Farrer NJ, Sadler PJ (2011) Bioinorganic Medicinal Chemistry. In: Alessio E, editors. Weinheim: Wiley-VCH, Germany, pp. 1–48.

Sigler JW, Bluhm GB, Duncan H, Sharp JT, Ensign DC, McCrum WR (1974) Gold Salts in the Treatment of Rheumatoid Arthritis: A Double-Blind Study. Ann Intern Med 80: 21–26. PubMed

Williams HJ, Ward JR, Reading JC, Brooks RH, Clegg DO, et al. (1992) Comparison of Auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis Rheum 35: 259–269. PubMed

Kean WF, Kean IRL (2008) Review: Clinical pharmacology of gold. Inflammopharmacology 16: 112–125. PubMed

Kean WF, Hart L, Buchanan WW (1997) Auranofin. Br J Rheumatol 36: 560–572. PubMed

Eisler R (2003) Chrysotherapy: a synoptic review. Inflamm Res 52: 487–501. PubMed

Bruijnincx PCA, Sadler PJ (2008) New trends for metal complexes with anticancer activity. Curr Opin Chem Biol 12: 197–206. PubMed PMC

Berners-Price SJ, Filipovska A (2008) The Design of Gold-Based, Mitochondria-Targeted Chemotherapeutics. Aust J Chem 61: 661–668.

Hambley TW (2007) Metal-Based Therapeutics. Science 318: 1392–1393. PubMed

Ott I (2009) On the medicinal chemistry of gold complexes as anticancer drugs. Coord Chem Rev 253: 1670–1681.

Milacic V, Dou QP (2009) The tumor proteasome as a novel target for gold(III) complexes: implications for breast cancer therapy. Coord Chem Rev 253: 1649–1660. PubMed PMC

Nardon C, Boscutti G, Fregona D (2014) Beyond platinums: gold complexes as anticancer agents. Anticancer Res 34: 487–492. PubMed

Casini A, Messori L (2011) Molecular mechanisms and proposed targets for selected anticancer gold compounds. Curr Top Med Chem 11: 2647–2660. PubMed

Che CM, Sun RW (2011) Therapeutic applications of gold complexes: lipophilic gold(III) cations and gold(I) complexes for anti-cancer treatment. Chem Commun (Camb). 47: 9554–9560. PubMed

Madeira JM, Gibson DL, Kean WF, Klegeris A (2012) The biological activity of auranofin: implications for novel treatment of diseases. Inflammopharmacology 20: 297–306. PubMed

Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K, et al. (1985) Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res 45: 32–39. PubMed

Simon TM, Kunishima DH, Vibert GJ, Lorber A (1979) Inhibitory effects of a new oral gold compound on HeLa cells. Cancer 44: 1965–1975. PubMed

Mirabelli CK, Johnson RK, Hill DT, Faucette L, Girard GR, et al. (1986) Correlation of the in vitro cytotoxic and in vivo antitumor activities of gold(I) coordination complexes. J Med Chem 29: 218–223. PubMed

Stallings-Mann M, Jamieson L, Regala RP, Weems C, Murray NR, et al. (2006) A novel small-molecule inhibitor of protein kinase Ciota blocks transformed growth of non-small-cell lung cancer cells. Cancer Res 66: 1767–1774. PubMed

Tiekink ERT (2008) Anti-cancer potential of gold complexes. Inflammopharmacology 16: 138–142. PubMed

Tiekink ERT (2002) Gold derivatives for the treatment of cancer. Crit Rev Hematol Oncol 42: 225–248. PubMed

Barreiro E, Casas JS, Couce MD, Sanchez-Gonzalez A, Sordo J, et al. (2008) Synthesis, structure and cytotoxicity of triphenylphosphinegold(I) sulfanylpropenoates. J Inorg Biochem 102: 184–192. PubMed

Casas JS, Castellano EE, Couce MD, Ellena J, Sánchez A, et al. (2006) A gold(I) complex with a vitamin K3 derivative: characterization and antitumoral activity. J Inorg Biochem 100: 1858–1860. PubMed

Casas JS, Castellano EE, Couce MD, Crespo O, Ellena J, et al. (2007) Novel Gold(I) 7-Azacoumarin Complex: Synthesis, Structure, Optical Properties, and Cytotoxic Effects. Inorg Chem 46: 6236–6238. PubMed

Ott I, Qian X, Xu Y, Kubutat D, Will J, et al.. (2009) A gold(I) phosphine complex containing naphthalimide ligand functions as a TrxR inhibiting antiproliferative agent and angiogenesis inhibitor. J Med Chem 52: , 763–770. PubMed

Gallassi R, Burini A, Ricci S, Pellei M, Rigobello MP, et al. (2012) Synthesis and characterization of azolate gold(I) phosphane complexes as thioredoxin reductase inhibiting antitumor agents. Dalton Trans 41: 5307–5318. PubMed

Serratrice M, Cinellu MA, Maiore L, Pilo M, Zucca A, et al. (2012) Synthesis, Structural Characterization, Solution Behavior, and in Vitro Antiproliferative Properties of a Series of Gold Complexes with 2-(2′-Pyridyl)benzimidazole as Ligand: Comparisons of Gold(III) versus Gold(I) and Mononuclear versus Binuclear Derivatives. Inorg Chem 51: 3161–3171. PubMed

Abbehausen C, Peterson EJ, de Paiva RE, Corbi PP, Formiqa AL, et al. (2013) Gold(I)-phosphine-N-heterocycles: biological activity and specific (ligand) interactions on the C-terminal HIVNCp7 zinc finger. Inorg Chem 52: 11280–11287. PubMed

Illán-Cabeza NA, García-García AR, Martínez-Martos JM, Ramírez-Expósito MJ, Pena-Riuz T, et al.. (2013) A potential antitumor agent, (6-amino-1-methyl-5-nitrosouracilato-N3)-triphenylphosphine-gold(I): Structural studies and in vivo biological effects against experimental glioma Eur. J. Med. Chem. 64 , 2013, 260–272. PubMed

Berners-Price SJ, Mirabelli CK, Johnson RK, Mattern MR, McCabe FL, et al. (1986) In Vivo Antitumor Activity and in Vitro Cytotoxic Properties of Bis[l,2-bis(diphenylphosphino)ethane]gold(I) Chloride. Cancer Res 46: 5486–5493. PubMed

Mirabelli CK, Hill DT, Faucette LF, McCabe FL, Girard GR, et al. (1987) Antitumor activity of bis(diphenylphosphino)alkanes, their gold(I) coordination complexes, and related compounds. J Med Chem 30: 2181–2190. PubMed

Berners-Price SJ, Jarrett PS, Sadler PJ, et al. (1987) 31P NMR Studies of [Au2(μ-dppe)2+)] Antitumor Complexes. Conversion into [Au(dppe)2]+ Induced by Thiols and Blood Plasma. Inorg Chem 26: 3074–3077.

Berners-Price SJ, Sadler PJ (1988) Phosphine and metal phosphine complexes: Relationship of chemistry to anticancer and other biological activity. Struct Bonding (Berlin) 70: 27–102.

Berners-Price SJ, Girard GR, Hill DT, Sutton BM, Jarrett PS, et al. (1990) Cytotoxicity and antitumor activity of some tetrahedral bis(diphosphino)gold(I) chelates. J Med Chem 33: 1386–1392. PubMed

Hickey JL, Ruhayel RA, Barnard PJ, Baker MV, Berners-Price SJ, et al. (2008) Mitochondria-targeted chemotherapeutics: the rational design of gold(I) N-heterocyclic carbene complexes that are selectively toxic to cancer cells and target protein selenols in preference to thiols. J Am Chem Soc 130: 12570–12571. PubMed

Rubbiani R, Kitanovic I, Alborzinia H, Can S, Kitanovic A, et al. (2010) Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties. J Med Chem 53: 8608–8618. PubMed

Trávníček Z, Štarha P, Vančo J, Šilha T, Hošek J, et al. (2012) Anti-inflammatory Active Gold(I) Complexes Involving 6-Substituted-Purine Derivatives. J Med Chem 55: 4568–4579. PubMed

Bzowska A, Kulikowska E, Shugar D (2000) Purine nucleoside phosphorylase: properties, functions, and clinical aspects. Pharmacol Ther 88: 349–425. PubMed

Bantia S, Miller PJ, Parker CD, Ananth SL, Horn LL, et al. (2001) Purine phosphorylase inhibitor BCX-1777 (Immucillin-H) – a novel potent and orally active immunosuppressive agent. Int Immunopharmacol 1: 1199–1210. PubMed

Clinch K, Evans GB, Fröhlich RFG, Furneaux RH, Kelly PM, et al. (2009) Third-Generation Immucillins: Syntheses and Bioactivities of Acyclic Immucillin Inhibitors of Human Purine Nucleoside Phosphorylase. J Med Chem 52: 1126–1143. PubMed PMC

Balakrishnan K, Verma D, O'Brien S, Kilpatrick JM, Chen Y, et al. (2010) Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia. Blood 116: 886–892. PubMed PMC

Vrzal R, Štarha P, Dvořák Z, Trávníček Z (2010) Evaluation of in vitro cytotoxicity and hepatotoxicity of platinum(II) and palladium(II) oxalato complexes with adenine derivatives as carrier ligands. J Inorg Biochem 104: 1130–1132. PubMed

Horvat UEI, Dobrzańska L, Strasser CE, Bouwer (neé Potgieter) W, Joone G, et al. (2012) Amides of gold(I) diphosphines prepared from N-heterocyclic sources and their in vitro and in vivo screening for anticancer activity. J Inorg Biochem 111: 80–90. PubMed

Štarha P, Trávníček Z, Popa A, Popa I, Muchová T, et al. (2012) Highly in vitro anticancer effective cisplatin derivatives involving halogeno-substituted 7-azaindole. J Inorg Biochem 115: 57–63. PubMed

Gáliková J, Trávníček Z (2014) Effect of different reaction conditions on the structural diversity of zinc(II) complexes with 9-deazahypoxanthine. Polyhedron 79: 269–276.

Zelová H, Hošek J (2013) TNF-alpha signalling and inflammation: interactions between old acquaintances. Inflamm Res 62: 641–651. PubMed

Dinarello CA (2011) A clinical perspective of IL-1 beta as the gatekeeper of inflammation. Eur J Immunol 41: 1203–1217. PubMed

Sims JE, Smith DE (2010) The IL-1 family: regulators of immunity. Nature Rev Immunol 10: 89–102. PubMed

Hayden MS, Ghosh S (2008) Shared principles in NF-kappa B signaling. Cell 132: 344–362. PubMed

Garber JC, Barbee RW, Bielitzki JT, Clayton LA, Donovan JC, et al... (2011) Guide for the Care and Use of Laboratory Animals, 8th ed., Washington: The National Academies Press, USA.

Mann FG, Wells AF, Purdie D (1937) The constitution of complex metalic salts: Part IV. The constitution of the phosphine and arsine derivatives of silver and aurous halides. The coordination of the coordinated argentous and aurous complex. J Chem Soc 1828–1836.

Bruce MI, Nicholson BK, Bin Shawkataly O (1989) Synthesis of gold-containing mixed-metal cluster complexes. Inorg Synth 26: 324–328.

Kamath VP, Juarez-Brambila JJ, Morris CB, Winslow CD, Morris PE Jr (2009) Development of a Practical Synthesis of a Purine Nucleoside Phosphorylase Inhibitor: BCX-4208. Org Process Res Dev 13: 928–932.

Gibson AE, Arris CE, Bentley J, Boyle FT, Curtin NJ, et al. (2002) Probing the ATP Ribose-Binding Domain of Cyclin-Dependent Kinases 1 and 2 with O6-Substituted Guanine Derivatives. J Med Chem 45: 3381–3393. PubMed

Oxford Diffraction, CrysAlis RED and CrysAlis CCD Software (Ver. 1.171.33.52), Oxford Diffraction Ltd., Abingdon, Oxfordshire, UK.

Sheldrick GM (2008) A short history of SHELX. Acta Crystallogr Sect A 64: 112–122. PubMed

Brandenburg K (2011) DIAMOND, Release 3.2i, Crystal Impact GbR, Bonn, Germany.

Rode HJ (2008) Apoptosis, Cytotoxicity and Cell Proliferation. 4th edition. Mannheim: Roche Diagnostics GmbH., Germany, 178 p.

Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(T)(-Delta Delta C) method. Methods 25: 402–408. PubMed

Zimmermann M (1983) Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109–110. PubMed

Chang HY, Sheu MJ, Yang CH, Leu ZC, Chang YS, et al... (2011) Analgesic effects and the mechanisms of anti-inflammation of hispolon in mice. Evid Based Complement Alternat Med (Article ID 478246) DOI: 10.1093/ecam/nep027. PubMed PMC

Salemi G, Gueli MC, D'Amelio M, Saia V, Mangiapane P, et al. (2009) Blood levels of homocysteine, cysteine, glutathione, folic acid, and vitamin B12 in the acute phase of atherothrombotic stroke. Neurol Sci 30: 361–364.. PubMed

Nakamoto K (1997) Infrared and Raman Spectra of Inorganic and Coordination Compounds, Part B: Applications in Coordination, Orgametallic and Bioinorganic Chemistry. fifth ed. New York: Wiley.

Faggianhi R, Howard-Locck HE, Lock CJL, Turner MA (1987) The reaction of chloro(triphenylphosphine)gold(I) with 1-methylthymine, Can J Chem. 65: 1568–1575.

Allen FH (2002) The Cambridge Structural Database: a quarter of a million crystal structures and rising. Acta Crystallogr Sect B Struct Sci 58: 380–388. PubMed

Hošek J, Vančo J, Štarha P, Paraková L, Trávníček Z (2013) Effect of 2-Chloro-Substitution of Adenine Moiety in Mixed-Ligand Gold(I) Triphenylphosphine Complexes on Anti-Inflammatory Activity: The Discrepancy between the In Vivo and In Vitro Models. Plos One 8: e82441. PubMed PMC

Seitz M, Valbracht J, Quach J, Lotz M (2003) Gold sodium thiomalate and chloroquine inhibit cytokine production in monocytic THP-1 cells through distinct transcriptional and posttranslational mechanisms. Journal of Clinical Immunology 23: 477–484. PubMed

Jeon KI, Jeong JY, Jue DM (2000) Thiol-reactive metal compounds inhibit NF-kappa B activation by blocking I kappa B kinase. Journal of Immunology 164: 5981–5989. PubMed

Abdel-Salam OME, Baiuomy AR, El-Shenawy SM, Arbid MS (2003) The anti-inflammatory effects of the phosphodiesterase inhibitor pentoxifylline in the rat. Pharmacol Res 47: 331–340. PubMed

Shaw CF, Coffer MT, Klingbeil J, Mirabelli CK (1988) Application of phosphorus-31 NMR chemical shift: gold affinity correlation to hemoglobin-gold binding and the first inter-protein gold transfer reaction. J Am Chem Soc 110: 729–734.

Iqbal MS, Taqi SG, Arif M, Wasim M, Sher M (2009) In vitro distribution of gold in serum proteins after incubation of sodium aurothiomalate and auranofin with human blood and its pharmacological significance. Biol Trace Elem Res 130: 204–209. PubMed

Saccoccia F, Angelucci F, Boumis G, Brunori M, Miele AE, et al. (2012) On the mechanism and rate of gold incorporation into thiol-dependent flavoreductases. J Inorg Biochem 108: 105–111. PubMed PMC

Lewis D, Capell HA, McNeil CJ, Iqbal MS, Brown DH, et al. (1983) Gold levels produced by treatment with auranofin and sodium aurothiomalate. Ann Rheum Dis 42: 566–570. PubMed PMC

The Gold(I) Complex with Plant Hormone Kinetin Shows Promising In Vitro Anticancer and PPARγ Properties

In vitro and in vivo anti-inflammatory active copper(II)-lawsone complexes

In Vitro Antitumor Active Gold(I) Triphenylphosphane Complexes Containing 7-Azaindoles

Structural Diversity of Copper(II) Complexes with 9-Deazahypoxanthine and Their in Vitro SOD-Like Activity